Advancing global health through internationally patented medical devices, novel pharmaceutical formulations, and the world's first in situ tissue-engineered trachea — translating over a decade of focused research into life-saving clinical innovations.
General Surgeon · Pulmonologist · Tissue Engineering Scientist
Dr. Jalaledin Ghanavi serves as the Head of the Tissue Engineering Department at the National Research Institute of Tuberculosis and Lung Diseases (NRITLD), affiliated with Shahid Beheshti University of Medical Sciences at Masih Daneshvari Hospital in Tehran, Iran.
With a dual specialization in general surgery and pulmonology, Dr. Ghanavi bridges the gap between clinical practice and translational research — pioneering regenerative approaches to airway reconstruction and developing novel pharmaceutical and biomedical products that have earned international recognition.
Under his leadership, the research team has successfully developed the world's first bio-artificial trachea using in situ tissue engineering methodology, a landmark achievement that eliminates the need for donor organs and immunosuppressive therapy in tracheal reconstruction.
"True innovation in medicine is not measured by complexity, but by the lives it transforms. Our mission is to bring laboratory breakthroughs to the bedside — safely, effectively, and accessibly."— Dr. Jalaledin Ghanavi, Founder
Converting scientific discoveries into clinically viable products with rigorous safety validation and regulatory compliance.
Every device and formulation is designed to minimize invasiveness, reduce side effects, and improve patient quality of life.
A robust portfolio of international patents protecting novel methods that define new standards in biotechnology.
From consumer health devices to clinical-grade pharmaceuticals, every product is rooted in rigorous science, validated through clinical testing, and protected by international patents.
The world's first product engineered to remove toxic compounds from hookah smoke. Hookahpo® neutralizes over 7,000 harmful chemicals — including 250 known carcinogens — as well as carbon monoxide, dramatically reducing the health risks associated with waterpipe use through advanced filtration technology.
A surgical and fabric mask protective spray formulated with a natural macrocycle molecule. Corona Safe deactivates the SARS-CoV-2 Spike (S) protein on contact, reducing viral transmission through masks by up to 60 times. Each application provides effective protection for up to 8 hours. Successfully passed all human biocompatibility tests.
An advanced wound management spray that forms a transparent, breathable protective film over wounds. Healina accelerates the natural healing process while providing a barrier against environmental contaminants and bacterial infection, suitable for surgical wounds and chronic wound care.
A novel pharmaceutical formulation developed for targeted therapeutic applications, combining active pharmaceutical ingredients with an optimized delivery system for enhanced bioavailability and controlled release, designed to improve patient compliance and clinical outcomes.
A combination pharmaceutical formulation designed for multi-target therapeutic action. Diclodipin represents an innovative approach to polypharmacy reduction by combining complementary active ingredients within a single dosage form, optimizing treatment efficiency.
The Tracheal Cuff Pressure Controlling Device ensures optimal endotracheal tube cuff pressure during mechanical ventilation, preventing tracheal injury. The HHO Gas Generation System represents an innovative approach to clean gas production for clinical and industrial applications.
Milestone achievements representing world-firsts in clinical biotechnology and public health protection — each validated through rigorous scientific methodology and clinical testing.
After 12 years of continuous research, Dr. Ghanavi and his team successfully transplanted the world's first bio-artificial trachea — achieved without conventional surgery or immunosuppressive drugs.
The breakthrough utilizes a pioneering "in situ tissue engineering" methodology: a biocompatible scaffold is injected at the target site, followed by guided stem cell differentiation into cartilage tissue, and precise placement of epithelial cells to reconstruct a fully functional airway segment within the patient's body.
This represents a paradigm shift in regenerative medicine — eliminating the need for donor organs and the lifelong burden of anti-rejection medication, opening new frontiers for tracheal reconstruction worldwide.
The Corona Safe protective spray was officially unveiled and commercialized at a ceremony held at Masih Daneshvari Hospital in Tehran. The product successfully passed all required human biocompatibility and safety testing protocols prior to market release.
The natural macrocycle molecule formulation was validated for its ability to deactivate the SARS-CoV-2 Spike protein, offering a practical, accessible layer of protection for healthcare workers and the general public during respiratory disease outbreaks.
Faculty of Medical Sciences — Research & Clinical Affiliation
National Research Institute of Tuberculosis & Lung Diseases
Certified by Iran's Vice Presidency for Science & Technology
Internationally protected intellectual property portfolio
Our multidisciplinary research spans from molecular biology to clinical application, driving innovations across six interconnected scientific domains.
Developing scaffold-based regenerative methodologies that enable tissue reconstruction directly within the patient's body, bypassing the need for external bioreactors and complex surgical transplantation.
Pioneering non-surgical tracheal repair using biocompatible scaffolds, directed stem cell differentiation into chondrocytes, and epithelial cell seeding for functional airway regeneration.
Formulating natural macrocycle molecule-based coatings that deactivate viral surface proteins on contact, creating new defensive layers for personal protective equipment.
Researching chemical neutralization of combustion byproducts — targeting carcinogens, heavy metals, and carbon monoxide in waterpipe smoke through novel filtration matrices.
Designing optimized pharmaceutical formulations with enhanced bioavailability, controlled release profiles, and combination therapies to improve patient compliance and outcomes.
Creating next-generation wound dressing technologies that form protective biofilms, accelerate re-epithelialization, and provide antimicrobial barriers for acute and chronic wound care.
Connect with our research & development headquarters in Tehran or our manufacturing facility in Qazvin for inquiries, partnerships, and procurement.